Search results
Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why
Zacks via Yahoo Singapore Finance· 2 years agoApellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria...
Apellis' (APLS) Q3 Earnings Miss Estimates, Revenues Top Mark
Zacks via Yahoo Singapore Finance· 2 years agoApellis Pharmaceuticals, Inc. APLS reported a loss per share of $1.75 for third-quarter 2022, wider...
4 Large Drug Stocks to Watch in a Booming Industry
Zacks via Yahoo Singapore Finance· 2 years agoDrug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ),...
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
Zacks via Yahoo Singapore Finance· 2 months agoAstraZeneca AZN announced its long-term plan to generate $80 billion in total revenues by 2030,...
Apellis (APLS) Rises on FDA Acceptance of NDA Amendment for GA
Zacks via Yahoo Singapore Finance· 2 years agoThe FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic...
US FTC sues to block Amgen's $27.8 billion deal for Horizon Therapeutics
Reuters via Yahoo Singapore Finance· 1 year agoWASHINGTON (Reuters) -The U.S. Federal Trade Commission said on Tuesday it has filed a lawsuit to...
California, other states join FTC bid to block Amgen deal
Reuters via Yahoo Singapore Finance· 1 year agoThe states of California, New York, Illinois, Minnesota, Washington and Wisconsin have joined a...
Novartis' (NVS) PNH Candidate Achieves Study Objectives
Zacks via Yahoo Singapore Finance· 2 years agoNovartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in...
AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication
Zacks via Yahoo Singapore Finance· 3 months agoFDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only...
Apellis (APLS) Files MAA for Pegcetacoplan in GA in Europe
Zacks via Yahoo Singapore Finance· 2 years agoApellis (APLS) submits a marketing authorization application for pegcetacoplan to treat geographic...